RMAX · Re/Max Holdings, Inc. · Stock research

Current Thesis

For eleven weeks RMAX was an arb with no spread and no date. Both of those changed in July. The DOJ granted early termination of the HSR waiting period on 2026-07-13, closing the antitrust leg outright, and the DEFM14A landed with hard dates: special meetings for both RE/MAX stockholders and Real securityholders on 2026-08-14, proxy deadline 10:00am ET 2026-08-12, record dates 2026-06-29 (REAX) and 2026-07-06 (RMAX).

The consideration is unchanged — each RMAX Class A share elects 5.150 New Wildlife shares or $13.80 cash, with cash prorated to an aggregate $60–80M. Against a $376M Class A market cap, roughly 16–21% of the equity clears in cash. With REAX at $2.21 (2026-07-15, +10.5% on the day) the stock leg marks 5.150 × $2.21 = $11.38, and the blended value with the cash pool sits near $11.86. RMAX closed $11.10, a ~6.5% discount that collapses inside six weeks if the vote passes.

That is the cleanest this situation has looked since April. It is also a leveraged REAX position wearing arb clothing: every $0.10 on REAX is $0.52 on the blended mark, and nothing about owning RMAX hedges that. The spread is compensation for acquirer beta, and only secondarily for completion risk.

Bullish and bearish views on Re/Max Holdings, Inc.

The model's bull view on Re/Max Holdings, Inc. (RMAX), in brief: Regulatory risk is gone, not reduced. DOJ early termination on 2026-07-13 is the strongest form of HSR clearance — the agency affirmatively ended the wait rather than letting it lapse. The condition most capable of killing a $880M EV brokerage rollup no longer exists. A dated… The bear view: The remaining risk is the risk that cannot be hedged in this instrument. Both cases follow in full.

Bull Case

• Regulatory risk is gone, not reduced. DOJ early termination on 2026-07-13 is the strongest form of HSR clearance — the agency affirmatively ended the wait rather than letting it lapse. The condition most capable of killing a $880M EV brokerage rollup no longer exists.
• A dated binary replaces an open-ended "H2 2026" guide. Meetings on 2026-08-14 for both sides, materials mailed, proxies due 2026-08-12. Arb capital prices dated deals differently from undated ones, which is a large part of why RMAX ran from ~$9.5 in late June to $11.10 and a 52-week high of $11.81.
• REAX has been repairing. From $1.68 (2026-06-07) to $2.21 (2026-07-15), +32%, with 6 covering analysts at Strong Buy and a consensus target of $3.73 (range $1.48–$5.68, 2026-07-16). REAX back to its $2.68 signing level marks RMAX blended near $14.20.
• The underlying housing tape stopped deteriorating. RE/MAX's own National Housing Report (2026-07-15) showed June closed sales +8.9% m/m and +7.8% y/y across 47 metros with a median at $460,000, versus May's -0.5% y/y. First positive annual print of the cycle.
• Break fees create friction: RMAX owes $25M to walk, REAX $31M plus a $36M regulatory termination fee.

Bear Case

• The remaining risk is the risk that cannot be hedged in this instrument. ~80% of consideration is REAX stock. REAX trades at $2.21 against a 52-week range of $1.55–$5.41; a retrace to the June low marks RMAX blended near $9.15, roughly 18% below spot, with the deal fully intact.
• REAX holders must approve dilution with their own stock down ~18% from signing. The $13.80 headline was struck against REAX's $2.68 close on 2026-04-24. Acquirer-side vote fatigue is the live tail, and it sits on the same date as the RMAX vote.
• Downside on a break is ~45%, back toward the pre-deal ~$6 area and the $5.46 52-week low. A 6.5% spread against a 45% break gap is a bet on completion probability well above 90% — defensible post-HSR, but it leaves no cushion for being wrong.
• Two mechanical conditions survive the vote: British Columbia court orders and a 10-for-1 Real share consolidation that restates the ratio to ~0.515 post-consolidation shares. Neither is likely to fail; both can slip the close.
• Nothing underneath supports $11.10 standalone. Q1 2026 (2026-05-08) printed revenue of $70.2M and a GAAP net loss of $(9.7)M; TTM revenue is $287.4M on trailing EPS of $0.02. Absent the deal this is a $6 stock.

Setup & Price Structure

• $11.10 close, $11.27 aftermarket, 52-week range $5.46–$11.81, YTD +46.3%. The stock is within 6% of its high, which for an arb means the discount has compressed, not that momentum is extending.
• Price action is derivative: -4.3% to $10.58 on 2026-07-10, then a recovery tracking REAX's +10.5% on 2026-07-15. Intraday RMAX prints follow REAX rather than its own order flow, and it has done so since April.
• The relevant structural level is not a moving average, it is ~$11.38 — the stock-leg mark at REAX $2.21. RMAX trading persistently below it measures arb-desk skepticism; trading above it measures cash-election demand.
• $9.50 is the level where the arb narrative breaks: it implies REAX back under $1.80 or the market handicapping the August vote as genuinely contested.
• Theme state: ACCELERATING within M&A/special-situations, on the specific and time-boxed basis of the HSR clearance and the vote date. This expires on 2026-08-14. It is not an accelerating narrative in the sense this playbook usually means — there is no story that gets bigger, only a discount that closes.

Catalyst Calendar (next 30 days)

• 2026-08-12, 10:00am ET — proxy voting deadline for both meetings.
• 2026-08-14 — special meetings, RMAX stockholders and REAX securityholders. The binary.
• ~2026-08-17 onward (est.) — BC court orders, 10-for-1 Real consolidation, then closing. Guided H2 2026; nothing after the vote requires a counterparty decision.
• ~2026-08-18 (est.) — RE/MAX July National Housing Report, on the mid-month cadence of the 2026-06-17 and 2026-07-15 releases.

Elapsed catalysts

• 2026-08-04 — RMAX Q2 2026 earnings. Largely academic to the arb; a large miss would matter only if it gave REAX holders a reason to vote no. (passed 5d ago)
• 2026-08-06 — REAX Q2 2026 earnings call. This one moves the stock leg 5.15:1 and is the higher-variance print of the two. (passed 3d ago)

What Would Change Our Mind

• A weekly close below $9.50 — the post-HSR floor fails, and either REAX has broken back under $1.80 or the vote is being handicapped as contested.
• Either meeting on 2026-08-14 failing, or being adjourned without a new date. Adjournment for vote-gathering is normal; adjournment without a date is the tell that the acquirer side is short.
• REAX losing $1.55, the 52-week low. That marks the stock leg at $7.98 and puts blended value below the pre-deal price, at which point RMAX holders are structurally better off with a break.
• On the upside: REAX reclaiming $2.68 with the vote passed marks blended value near $14.20 and converts what is currently a six-week discount into a position in the combined 180,000-agent entity at ~$2.3B pro forma revenue and ~$157M adjusted EBITDA, with ~$30M of targeted cost synergies.
• Spread widening back above 12% without a news reason would be the signal to look harder rather than to buy — arb desks see the S-4 risk factors first.

Correlation Notes

• REAX is not a correlation, it is the underlying. RMAX's beta to REAX is ~0.85 realized and 1.0 by construction on the stock leg. Any position sizing that treats RMAX and REAX as two names is double-counting the same exposure.
• Second-order sensitivity to residential-brokerage comps — COMP, EXPI, HOUS, ZG — via the read-through on agent-count trends and commission splits, which is what REAX holders will be voting on.
• Rate-sensitive housing complex (homebuilders, mortgage originators) is a weak driver here. The June sales acceleration helps sentiment on the combined entity; it does not move the arb math.
• Effectively zero correlation to the broad tape between now and 2026-08-14, and total correlation to it if the deal breaks. That regime switch is the whole risk profile.